KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Change in Cash (2016 - 2025)

Historic Change in Cash for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to -$595.2 million.

  • Edwards Lifesciences' Change in Cash fell 12938.82% to -$595.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$988.6 million, marking a year-over-year decrease of 14356.03%. This contributed to the annual value of $1.9 billion for FY2024, which is 40900.37% up from last year.
  • According to the latest figures from Q3 2025, Edwards Lifesciences' Change in Cash is -$595.2 million, which was down 12938.82% from $141.2 million recorded in Q2 2025.
  • Edwards Lifesciences' Change in Cash's 5-year high stood at $2.0 billion during Q3 2024, with a 5-year trough of -$652.5 million in Q4 2021.
  • Its 5-year average for Change in Cash is $78.7 million, with a median of $103.8 million in 2023.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 48224.96% in 2021, then soared by 190537.63% in 2022.
  • Quarter analysis of 5 years shows Edwards Lifesciences' Change in Cash stood at -$652.5 million in 2021, then grew by 26.57% to -$479.1 million in 2022, then skyrocketed by 44.5% to -$265.9 million in 2023, then plummeted by 134.9% to -$624.6 million in 2024, then increased by 4.71% to -$595.2 million in 2025.
  • Its Change in Cash stands at -$595.2 million for Q3 2025, versus $141.2 million for Q2 2025 and $90.0 million for Q1 2025.